Claude Gardin

10.3k total citations · 1 hit paper
123 papers, 4.3k citations indexed

About

Claude Gardin is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Claude Gardin has authored 123 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Hematology, 40 papers in Genetics and 39 papers in Molecular Biology. Recurrent topics in Claude Gardin's work include Acute Myeloid Leukemia Research (87 papers), Acute Lymphoblastic Leukemia research (25 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers). Claude Gardin is often cited by papers focused on Acute Myeloid Leukemia Research (87 papers), Acute Lymphoblastic Leukemia research (25 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers). Claude Gardin collaborates with scholars based in France, Italy and United States. Claude Gardin's co-authors include Hervé Dombret, Pierre Fenaux, Emmanuel Raffoux, Sylvie Castaigné, Cécile Pautas, Xavier Thomas, Lionel Adès, Christine Terré, Pascal Turlure and Claude Preudhomme and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Claude Gardin

117 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An update of current treatments for adult acute myeloid leukemia

2015 388 citations Hervé Dombret, Claude Gardin Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claude Gardin France	35	3.2k	1.9k	1.1k	800	750	123	4.3k
Sherry Pierce United States	36	3.5k 1.1×	1.8k 0.9×	1.3k 1.2×	971 1.2×	897 1.2×	131	4.5k
Maria Concetta Petti Italy	32	2.9k 0.9×	2.0k 1.0×	811 0.7×	698 0.9×	625 0.8×	112	3.7k
Vinod Pullarkat United States	38	3.8k 1.2×	1.9k 1.0×	1.4k 1.2×	1.3k 1.6×	1.2k 1.6×	228	6.0k
Ellin Berman United States	31	2.2k 0.7×	1.2k 0.6×	992 0.9×	871 1.1×	1.2k 1.6×	99	3.8k
Ghulam Mufti United Kingdom	27	4.7k 1.5×	1.2k 0.6×	2.0k 1.7×	790 1.0×	818 1.1×	101	5.8k
Bart L. Scott United States	35	3.8k 1.2×	1.0k 0.5×	1.6k 1.4×	1.0k 1.3×	509 0.7×	169	4.3k
Mar Tormo Spain	32	2.1k 0.6×	1.3k 0.7×	506 0.5×	1.0k 1.3×	646 0.9×	106	3.1k
Ellen K. Ritchie United States	30	2.4k 0.8×	1.4k 0.7×	1.2k 1.1×	736 0.9×	678 0.9×	172	3.6k
Jan Starý Czechia	42	3.1k 1.0×	1.5k 0.8×	570 0.5×	2.4k 3.0×	1.0k 1.4×	255	5.0k
Michael Rytting United States	31	2.1k 0.6×	1.1k 0.6×	656 0.6×	2.1k 2.6×	1.3k 1.8×	96	4.2k

Countries citing papers authored by Claude Gardin

Since Specialization

Citations

This map shows the geographic impact of Claude Gardin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claude Gardin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claude Gardin more than expected).

Fields of papers citing papers by Claude Gardin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claude Gardin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claude Gardin. The network helps show where Claude Gardin may publish in the future.

Co-authorship network of co-authors of Claude Gardin

This figure shows the co-authorship network connecting the top 25 collaborators of Claude Gardin. A scholar is included among the top collaborators of Claude Gardin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claude Gardin. Claude Gardin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hueso, Thomas, Grégory Lazarian, Adrien Chauchet, et al.. (2025). Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis. eJHaem. 6(2). e70019–e70019.

Duployez, Nicolas, Juliette Lambert, Maël Heiblig, et al.. (2023). Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML. Blood. 142(Supplement 1). 4322–4322.

Rahmé, Ramy, Valérie Vidal, Thomas Hueso, et al.. (2023). Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience. Blood. 142(Supplement 1). 1520–1520. 2 indexed citations

Berrou, Jeannig, Emmanuelle Clappier, Jean‐Michel Cayuela, et al.. (2022). Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL). Journal of Clinical Medicine. 11(22). 6761–6761. 4 indexed citations

Duployez, Nicolas, Matthieu Duchmann, Laëtitia Largeaud, et al.. (2021). Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study. Blood. 138(Supplement 1). 612–612.

Berrou, Jeannig, Jan E. Ehlert, Holger Weber, et al.. (2020). Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. Leukemia Research. 100. 106490–106490. 8 indexed citations

Kelaïdi, Charikleia, Thorsten Braun, Alice Marceau‐Renaut, et al.. (2018). Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research. 71. 67–74. 3 indexed citations

Adès, Lionel, Xavier Thomas, Emmanuel Raffoux, et al.. (2018). Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica. 103(12). 2033–2039. 21 indexed citations

Grignano, Éric, A. Mékinian, Thorsten Braun, et al.. (2016). Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leukemia Research. 47. 136–141. 36 indexed citations

10.

Adès, Lionel, Thomas Prébet, Aspasia Stamatoullas, et al.. (2016). Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies. Haematologica. 102(4). 728–735. 21 indexed citations

11.

Itzykson, Raphaël, Claude Gardin, Cécile Pautas, et al.. (2011). Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica. 96(6). 837–844. 16 indexed citations

12.

Thomas, Xavier, Emmanuel Raffoux, Aline Renneville, et al.. (2010). Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study. Cancer. 116(7). 1725–1732. 16 indexed citations

13.

Boehrer, Simone, Lionel Adès, Nicolas Tajeddine, et al.. (2009). Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene. 28(22). 2205–2218. 43 indexed citations

14.

Kiladjian, Jean‐Jacques, Francisco Cervantes, Frank W.G. Leebeek, et al.. (2008). The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 111(10). 4922–4929. 227 indexed citations

15.

Adès, Lionel, Simone Boehrer, Thomas Prébet, et al.. (2008). Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 113(17). 3947–3952. 107 indexed citations

16.

Taksin, A.-L., Ollivier Legrand, Emmanuel Raffoux, et al.. (2006). High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 21(1). 66–71. 226 indexed citations

17.

Mannone, Lionel, Claude Gardin, Jérôme Bernard, et al.. (2006). High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology. 133(5). 513–519. 72 indexed citations

18.

Hillaire, Sophie, Claude Gardin, A. Attar, et al.. (2000). Cholangiopathy and intrahepatic stones in sickle cell disease: coincidence or ischemic cholangiopathy?. The American Journal of Gastroenterology. 95(1). 300–301. 19 indexed citations

19.

Kiladjian, Jean‐Jacques, Nahed El-Kassar, Gilles Hetet, et al.. (1997). Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia. 11(11). 1821–1826. 56 indexed citations

20.

Gardin, Claude, Pascal Chaı̈bi, Thierry de Revel, et al.. (1997). Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia. 11(1). 16–21. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact